CXCL8 and medullary thyroid gland carcinoma: More importantly, CXCL8 was identified as a potential biomarker of sunitinib responsiveness, because in vivo the circulating levels of CXCL8 dramatically decreased following sunitinib administration in medullary thyroid cancer xenografts (123).